Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland Join List of Canadian Provinces Providing Public Drug Plan Reimbursement for Teva Canada's Ajovy for the Preventive Treatment of Migraine in Adults
18 May 2022 - - Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) (TASE: TEVA) Teva Canada Ltd subsidiary of., welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, the company said.

In early March 2022, Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program announced similar public formulary coverage.

Ajovy is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. Public formulary coverage will help make Ajovy accessible to more patients across Canada.

Teva Canada hopes that other public drug plans across Canada will soon make Ajovy available to the eligible patients in their jurisdictions.

Ajovy is available in two formats and two dosing regimens, giving prescribers and patients treatment flexibility to help suit their needs. Ajovy is supported by the Ajovy Teva Support Solutions (Ajovy TSS) Patient Support Program.

Migraine is a disabling chronic neurological disease that causes head pain so severe that sufferers often cannot function during an attack. Migraine reduces quality of life and disrupts migraineurs' ability to perform daily activities.

It is among the top 10 causes of disability worldwide and the seventh cause of years of life lost to disability.

In Canada, migraine is most common in women and most common between the ages of 30 and 49.

Migraine therefore reduces patients' quality of life, ability to work, and overall productivity right at the prime of their life.

While acute treatment modalities are used to treat migraine attacks when they occur, they do not prevent them. Novel treatments like Ajovy were specifically designed to prevent migraine from occurring.

Ajovy (fremanezumab) is indicated for the preventive treatment of migraine in adults who have at least four migraine days per month.

Ajovy is available as a 225 mg/1.5 mL single-dose injection in an autoinjector or prefilled syringe with two dosing options: 225 mg monthly, administered as one subcutaneous injection; or 675 mg every three months (quarterly), administered as three subcutaneous injections.

Ajovy is intended for patient self-administration after the patient or their caretaker has been trained to administer the product.

Ajovy patients and prescribers are supported by the Ajovy Teva Support Solutions Patient Support Program.

Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, building their trust one prescription at a time with now more than 290,000 prescriptions filled each day with our products, representing 1 of every 5 generic prescriptions in Canada.

The company specializes in the development, production, and marketing of high-quality generic prescription pharmaceuticals and, through our branded division, focuses on a diverse line of speciality and biopharmaceutical products in a variety of therapeutic areas such as central nervous system, respiratory, oncology and rheumatology.

Teva Canada's commitment to helping improve the lives of Canadians also extends to the Teva Caregiver program providing tools and resources for Canadians navigating the care journey.

Teva Canada employs more than 900 professionals, had sales of nearly USD 1.2bn in 2021, and markets more than 32020 products in over 93520 SKUs in Canada. We are a proud subsidiary of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical is in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.